CAR T-cell therapy for multiple myeloma: state of the art and prospects

This review describes the pharmacology of chimeric antigen receptor T (CAR-T) cell therapy, and the various phase III trials that are underway and have completed. It also discusses the possibility of optimising CAR design by enriching for specific subsets of T cells.

Source:

The Lancet Haematology